Avalo Therapeutics AVTX
NASDAQ AVTX
$14.95 -0.38 (-2.48%)
At close: Oct 1, 2026 · 4:00 PM EDT

Avalo Therapeutics (AVTX) Liabilities and Shareholders Equity (2014 - 2026)

Updated

Avalo Therapeutics (AVTX) recorded Liabilities and Shareholders Equity of $490.78 million in Q2 2026, up 287.7% from $126.58 million a year earlier and up 391.3% from the prior quarter.

Analysis

Avalo Therapeutics (AVTX) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends

At the end of FY2025, Avalo Therapeutics reported Liabilities and Shareholders Equity of $116.46 million, down 22.7% from FY2024.

  • Annual Liabilities and Shareholders Equity has a five-year compound annual growth rate of 21.6% (FY2020 to FY2025).
  • Across earlier years, Liabilities and Shareholders Equity came in at $150.73 million in FY2024 (+618.0%), $20.99 million in FY2023 (-37.1%), $33.37 million in FY2022 (-58.4%) and $80.21 million in FY2021 (+83.3%).
  • The Q2 2026 figure is the highest quarterly Liabilities and Shareholders Equity in data going back to Q4 2014.
  • On a year-over-year basis, Liabilities and Shareholders Equity rose in six of the last eight quarters, with growth averaging 143.4%.
  • Peak year-over-year performance for Liabilities and Shareholders Equity in the last five years was growth of 618.0% in Q4 2024, against a decline of 61.7% in Q3 2022 at the low end.
  • Per Business Quant, the preceding three quarters came in at $99.89 million (Q1 2026), $116.46 million (Q4 2025) and $125.1 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Avalo Therapeutics 668.42 Mn 668.42 Mn - 490.78 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 490.78 Mn
Mar 31, 2026 99.89 Mn
Dec 31, 2025 116.46 Mn
Sep 30, 2025 125.10 Mn
Jun 30, 2025 126.58 Mn
Mar 31, 2025 138.52 Mn
Dec 31, 2024 150.73 Mn
Sep 30, 2024 98.46 Mn
Jun 30, 2024 108.31 Mn
Mar 31, 2024 123.73 Mn
Dec 31, 2023 20.99 Mn
Sep 30, 2023 29.27 Mn
Jun 30, 2023 24.24 Mn
Mar 31, 2023 36.24 Mn
Dec 31, 2022 33.37 Mn
Sep 30, 2022 36.55 Mn
Jun 30, 2022 32.22 Mn
Mar 31, 2022 61.90 Mn
Dec 31, 2021 80.21 Mn
Sep 30, 2021 95.36 Mn
API Access

Avalo Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=AVTX&period=max&api_key=YOUR_API_KEY